Kedudukan dalam Saham
#13334
Sensorion SA, a clinical-stage biopharmaceutical company, develops drug... Sensorion SA, a clinical-stage biopharmaceutical company, develops drug candidates for the treatment of inner ear disorders in France. The company develops OTOF-GT, a gene therapy development program to restore hearing in people living with Otoferlin deficiency; USHER-T1-GT, a gene therapy development program to for patients suffering from usher syndrome Type 1; and SENS-401, a drug candidate to treat sudden sensorineural hearing loss. Its pipeline also includes various products in development stage for restoring, treating, and preventing inner ear related disorders. The company has a collaboration agreement with Institut Pasteur for gene therapy program for pediatric and adult deafness; and with Sonova Holding AG to introduce genetic analysis for routine diagnosis of progressive hearing loss in adults through a combination of advanced therapeutic interventions and traditional hearing aids. Sensorion SA was founded in 2009 and is headquartered in Montpellier, France.
Perubahan (1 hari)
-0.96%
Perubahan (1 tahun)
-35.23%
Perdagangan Sensorion SA (ALSEN)
Harga ALSEN dengan permodalan pasaran b
Modal pasaran bagi Sensorion SA(ALSEN)
Modal Pasaran: $93.46M
Sehingga July 2026, Sensorion SA mempunyai modal pasaran sebanyak $93.46M. Ini menjadikan Sensorion SA syarikat ke-13334th paling bernilai di dunia mengikut data kami. Kapitalisasi pasaran ialah nilai keseluruhan saham syarikat tersenarai yang berada dalam edaran dan lazimnya digunakan untuk menilai nilai syarikat tersebut.
Sejarah modal pasaran Sensorion SA dari 2015 hingga 2026
ALSEN berbanding dengan 5 teratas yang paling popular stocks
| Harga ALSEN |
|
Aset B |
Pasaran B |
Hasilnya |
|
|
|
|
$5.110T
|
+5,466,937.08%
|
|
|
|
|
$4.631T
|
+4,955,029.08%
|
|
|
|
|
$4.320T
|
+4,622,094.12%
|
|
|
|
|
$2.861T
|
+3,060,667.82%
|
|
|
|
|
$2.639T
|
+2,823,631.51%
|
